> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Approves Lilly Interchangeable Insulin Product
- URL: https://www.fdaweb.com/fda-approves-lilly-interchangeable-insulin-product/
- Published: 2022-11-17T12:00:00.000Z
- Updated: 2026-09-14T18:06:54.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5153221

FDA has approved Lilly’s Rezvoglar (insulin glargine-aglr) as an interchangeable biosimilar insulin product to Sanofi’s Lantus (insulin glargine). The agency says [Rezvoglar](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761215&ref=fdaweb.com) is a long-acting human insulin analog indicated to approve glycemic control in adults and pediatric patients with diabetes mellitus. FDA previously approved Rezvoglar as a Lantus biosimilar on 12/17/21.

Interchangeable biosimilars have met additional requirements so they may be substituted for the reference product at the pharmacy if state laws permit, FDA says. Rezvoglar is available in 3 mL prefilled pens and is administered subcutaneously once daily. It joins Mylan’s Semglee (insulin glargine-yfgn) as an interchangeable biosimilar insulin.